Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses
To access this article, please choose from the options below
The statistical analysis of the entire data sets pertaining to efficacy and safety was performed independently by a biostatistician (C.–L. Chen, National Taiwan University College of Medicine) who is not employed by the corporate entity.
The corresponding authors (D.–S. Chen and P.–J. Chen) had full access to all of the data and take full responsibility for the veracity of the data and analysis. The study sponsors did not play any role in the study design; in the collection, analysis, and interpretation of data; and in the decision to submit the report for publication.
US National Institutes of Health registration number for clinical trial: NCT00361179. An Open Label, Comparative, Multi-Center Study, To Evaluate the Efficacy and Safety of Peginterferon Alfa-2a Plus Ribavirin in the Treatment of Patients With Chronic Hepatitis C/Hepatitis B Co-Infection and Chronic Hepatitis C.
The authors disclose the following: This study was supported in part by grants from the Department of Health, the National Science Council, Executive Yuan, Taiwan; National Taiwan University; and National Health Research Institutes, Taiwan.
PII: S0016-5085(08)01887-8
doi:10.1053/j.gastro.2008.10.049
© 2009 AGA Institute. Published by Elsevier Inc. All rights reserved.
Refers to article:
- Treatment of HBV/HCV Coinfection: Releasing the Enemy Within , 22 December 2008

